Triple Negative Breast Cancer (TNBC)
1) TNBC is the most difficult subtype of breast cancer to treat
2) Has a high rate of recurrence within 3 years with residual cancer burden
3) A 5-year survival rate with distant metastases of only 12%
4) Accounts for 40% of all breast cancer-related mortality
Solutions
iEF Therapy Data
(in vivo – 4T1 model)
(in vivo – 4T1 model)
iEF Science
EMBioSys’ iEF therapy works both at the cellular level targeting only cancer cells, and at the tissue, organ, and organism levels using a 4-pronged approach:
1) iEFs alter the cancer cell’s cytoskeleton making it unable to move
2) iEFs metabolically deprives cells of much-needed energy to move and proliferate
3) iEFs reverse epithelial-to-mesenchymal transition (EMT) preventing detachment
4) iEFs enhance immune response by attracting anti-tumor immune cells and dissuading pro-tumor immune cells both at primary and metastatic sites
News
03/12/2025
EMBioSys is excited to announce that Sachin Jhawar, MD has joined our Advisory Board!
Dr. Jhawar specializes in Radiation Oncology with a focus on breast cancer, skin cancer and head & neck cancer at The James Comprehensive Cancer Center in Columbus Ohio. We look forward to Dr. Jhawar’s contribution towards our mission to dramatically improve cancer patient outcomes using our novel iEF Therapy.
03/12/2025
We are pleased to announce that EMBioSys Co-Founder and CEO, Chris Barron will be presenting at the LSI USA Emerging Medtech Summit on March 19, 2025. This is a great opportunity to share the latest advancements for our iEF Therapy that offers new hope for women diagnosed with triple-negative breast cancer.
03/06/2025
We are pleased to announce that Dr. Vish Subramaniam, EMBioSys Co-Founder and Chief Scientific Officer, will be presenting a poster at the American Association for Cancer Research (AACR) on April 28, 2025.
Dr. Subramaniam’s poster will focus on practical methods for delivering iEF (induced electric field) therapy for treatment of solid cancers, starting with triple-negative breast cancer.
Backed by over a decade of pre-clinical research and publications, iEF Therapy has demonstrated in animal models the ability to inhibit pulmonary metastasis, reduce tumor growth, boost the natural anti-tumor immune response, and in vitro improved cytotoxic activity of standard of care chemotherapeutic agents, all while selectively targeting only cancer cells.
We look forward to sharing the details of our compelling technology with the cancer community at the AACR meeting.
01/17/2025
EMBioSys is proud to acknowledge our entire team of research partners at The Ohio State University for their important contributions towards the development of iEF Therapy for treatment of breast cancer. Special congratulations to Dr. Manish Charan from Dr. Ramesh Ganju’s group for their iEF presentation that placed 3rd at the at the Great Lakes Breast Cancer Research Symposium in October, 2024.
In December 2024, this important work was also presented at the American Association of Cancer Research’s San Antonio Breast Cancer Symposium, and won the Advocate Choice Award from GRASP Cancer. GRASP Cancer unites patients, clinicians, and researchers to exchange ideas, share insights, and jointly accelerate scientific breakthroughs.
The recognition of this impactful research further supports our mission at EMBioSys to improve patient outcomes for treatment of breast cancer.
09/11/2024
EMBioSys is honored to announce that our President and Chief Scientific Officer, Dr. Vish Subramaniam, has been asked to present at the Cancer Bioelectricity Conference sponsored by the National Cancer Institute on September 12th, 2024.
Dr. Subramaniam will be speaking about “Technologies for treatment of Metastatic Solid Tumors”, including EMBioSys’ iEF Therapy. One of the key goals of the conference is to disseminate the science of bioelectricity and its potential applications towards cancer treatments to a diverse audience. The National Cancer Institute’s support for research and development of bioelectricity is an important step in the evolution of life-saving technologies for cancer patients in the future.
Link to the event site and agenda: https://cam.cancer.gov/news_and_events/conferences.htm
08/21/2024
EMBioSys is excited to be selected among the first 100 Innovators to present at LSI USA, March 17th – 21st, 2025! Looking forward to the event!
07/01/2024
EMBioSys is pleased to announce that Tracey Wielinski has joined our Advisory Board. Tracey is a Regulatory, Clinical and Quality executive with 30 years of experience in the Medical Device and Pharmaceutical space focused on strategic, global product realization and compliant business processes. We are looking forward to having Tracey on the team to advise us, as we move towards clinical trials.
06/25/2024
We are excited to announce that Rick Clemon has joined our Advisory Board!
Rick is a CFO with 30 years of experience spanning diverse sectors, including development and clinical-stage life science and medical device companies advancing research and development across pharmaceuticals, biologics, therapies, and assistive technologies focused on cancers, retinal disease, and kidney disease. Rick’s wisdom, enthusiasm, and passion for our mission will surely be a tremendous asset as EMBioSys moves towards clinical trials in humans.
06/18/2024
We are honored to announce that Silvia C. Formenti, MD has joined our Advisory Board!
Dr. Formenti is Chair of the Department of Radiation Oncology at Weill Cornell Medicine, and Radiation Oncologist-in-Chief at NewYork-Presbyterian Hospital. She is a recognized leader in cancer research, experienced in translating preclinical work into clinical trials in metastatic breast cancer, lung cancer, and melanoma.
05/09/2024
EMBioSys is excited to announce that we have received a Small Business Innovation Research (SBIR) Phase 1 Award from the National Cancer Institute for Development of a Wearable, Non-invasive, Treatment Device for Metastatic Triple-Negative Breast Cancer (TNBC). We are grateful to the NIH/NCI in recognizing the potential of our therapeutic induced electric field (iEF) technology towards improving treatment outcomes and potentiating standard of care for treatment of solid metastatic cancers.
We look forward to collaborating with our research partners at The Ohio State University on this award.
04/30/2024
We are honored to announce that Joe Camardo, MD has officially joined EMBioSys as a Medical Advisor. Joe is a Board Certified General Internist with 30 years of drug development experience in multiple areas, including oncology, inflammation, vaccines, neuroscience, and roles as head of clinical research and medical affairs.
Since our iEF therapy potentiates standard of care including chemotherapy, Joe’s experience will surely help us navigate the fastest path to market, and saving lives.
02/01/2024
We are trilled to announce that Jennifer Herron has joined EMBioSys as an Independent Board Director and Strategic Advisor! Jennifer’s dedication to our mission is humbling, and we are grateful for her guidance and passion.
Silvia C. Formenti, MD
Chair of the Department of Radiation Oncology at Weill Cornell Medicine, and Radiation Oncologist-in-Chief at NewYork-Presbyterian Hospital; A recognized leader in cancer research, experienced in translating preclinical work into clinical trials in metastatic breast cancer, lung cancer, and melanoma
Sachin Jhawar, MD
Dr. Jhawar specializes in Radiation Oncology with a focus on breast cancer, skin cancer and head & neck cancer at The James Comprehensive Cancer Center in Columbus Ohio
Rick Clemon, CPA, CGMA
CFO with 30 years of experience spanning diverse sectors, including development and clinical-stage life science and medical device companies advancing research and development across pharmaceuticals, biologics, therapies, and assistive technologies focused on cancers, retinal disease, and kidney disease
© 2025 EMBioSys Inc. All rights reserved.
